- Home
- SAVA vs FENC Comparison
SAVA vs FENC Comparison
Compare SAVA & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- FENC
- Stock Information
- Founded
- SAVA 1998
- FENC 1996
- Country
- SAVA United States
- FENC United States
- Employees
- SAVA N/A
- FENC N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAVA Health Care
- FENC Health Care
- Exchange
- SAVA Nasdaq
- FENC Nasdaq
- Market Cap
- SAVA 137.2M
- FENC 156.9M
- IPO Year
- SAVA N/A
- FENC 2001
- Fundamental
- Price
- SAVA $1.38
- FENC $5.53
- Analyst Decision
- SAVA Buy
- FENC Strong Buy
- Analyst Count
- SAVA 3
- FENC 2
- Target Price
- SAVA $54.50
- FENC $14.00
- AVG Volume (30 Days)
- SAVA 2.2M
- FENC 126.0K
- Earning Date
- SAVA 05-09-2025
- FENC 05-13-2025
- Dividend Yield
- SAVA N/A
- FENC N/A
- EPS Growth
- SAVA N/A
- FENC N/A
- EPS
- SAVA N/A
- FENC N/A
- Revenue
- SAVA N/A
- FENC $47,538,000.00
- Revenue This Year
- SAVA N/A
- FENC $2.68
- Revenue Next Year
- SAVA N/A
- FENC $71.63
- P/E Ratio
- SAVA N/A
- FENC N/A
- Revenue Growth
- SAVA N/A
- FENC 123.69
- 52 Week Low
- SAVA $1.35
- FENC $3.96
- 52 Week High
- SAVA $42.20
- FENC $11.29
- Technical
- Relative Strength Index (RSI)
- SAVA 23.37
- FENC 30.64
- Support Level
- SAVA $1.63
- FENC $6.25
- Resistance Level
- SAVA $1.79
- FENC $6.90
- Average True Range (ATR)
- SAVA 0.19
- FENC 0.36
- MACD
- SAVA -0.14
- FENC -0.09
- Stochastic Oscillator
- SAVA 1.76
- FENC 4.20
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.